Cerus Endovascular receives FDA approval for its first microcatheter. The 021 microcatheter will be offered with three different distal configurations, and commercial sales are expected to begin during the second quarter of 2020.
According to a press release, the company will be developing additional microcatheters of various dimensions to offer a comprehensive selection of instrumentation for the needs of interventional neuroradiologists.
Moreover, the company announced it has successfully completed its Series B financing that has raised a total of US$19 million from current and new institutional investors since the commencement of the round in July 2018.
Completion of the Series B financing will allow the company to execute on its go-to-market strategy and to complete the planned expansion of its product portfolio, including a smaller delivery platform for its recently CE marked Contour Neurovascular System, for the treatment of intracranial aneurysms.
The company’s second implant device, the Neqstent aneurysm bridging device, is advancing through the regulatory process, with a clinical trial currently enrolling, aimed at providing additional safety and efficacy data. The Neqstent is designed to be used in conjunction with conventional embolic coils for endovascular embolisation of bifurcated saccular intracranial aneurysms.